SLC22A12 and hyperuricemia: Lesinurad, a novel URAT1 inhibitor developed by Ardea Biosciences and AstraZeneca, was approved by the FDA at the end of 2015 for the treatment of hyperuricemia associated with gout in combination with an XOI [19].